http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2129878-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13d04b1195cf701d729abf73280a0176 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3a71ad89233de4a83b1afbc2f3b6148 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bffe081a1f09041e58770f90c3964e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b75b0cc6d1aff6370bc787f9bfea1d27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c697e0f73dc973e0af66a2418a1abb2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74a2d71a1c0915033fde6db306f338bb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 1996-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1999-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d707dc3bc2584972bce3b602d25fc4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_748f5e0f87ba6bf83667c055f1780e10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a9e4ac57f4507e0f258125c0ee38c2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22c39c573abd0fe9542634a6cf5f9f16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba86b08eadc799f23fd598596b70b5bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8085c466bbc0f8ef9fc55809de8641c6 |
| publicationDate | 1999-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2129878-C1 |
| titleOfInvention | Immunomodulating preparation "neoferon" showing antiviral activity |
| abstract | FIELD: biotechnology, pharmacy, veterinary science. SUBSTANCE: invention relates to preparing ready medicinal forms showing immunomodulating and antiviral properties as a lyophilized form for parenteral administration and in tablets for per os ingestion. Preparation has a complex consisting of the following recombinant cytokines: 1) hybrid protein T-FNO-T isolated from microorganism where recombinant plasmid pThy-325 encoding protein synthesis is introduced; 2) interferon alpha-2 isolated from the strain E. coli containing plasmid pTTαKm-1,4 encoding protein; 3) interferon-gamma isolated from the strain Escherichia coli MC-106 containing plasmid (pTTγKm2)T3γ encoding protein. For parenteral administration (form 1) the preparation is prepared at the following ratio of components in volume 1cm 3 : hybrid protein T-FNO-T 0.0000001%; interferon alpha-2 0.0000001-0.0000002%; interferon-gamma 0.0000001-0.0000002%; polyglucin 1.5-2.0%; saline buffer system, pH 7.0-7.2, 1.03-1.06%, apyrogenic water - the rest. Buffered physiological sodium chloride solution is used as a saline buffer system. For oral administration (form 2) the preparation is prepared at the following ratio of components, per 1 tablet, wt.-%: hybrid protein T-FNO-T 0.00000005%; interferon alpha-2 0.00000005%; interferon-gamma 0.0000001-0.0000002%; aluminium hydroxide 4-5%; starch 3-4%; calcium (magnesium) stearate 0.2-0.25%, glucose hydrate - the rest. Preparation shows immunomodulating activity and can be used for the complex nonspecific prophylaxis in treatment of patients with infectious sicknesses. EFFECT: enhanced immunomodulating and an antiviral activity. 4 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3789035-A4 |
| priorityDate | 1996-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.